(MedPage Today) — TORONTO — The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer’s disease, data from the long-term extension of the TRAILBLAZER-ALZ 2 trial suggested.
Compared with…
Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116791
Author :
Publish date : 2025-08-01 18:42:00
Copyright for syndicated content belongs to the linked Source.
